Funders › MA › Alzheimer's Disease Research Foundation › 2019
Grants paid by Alzheimer's Disease Research Foundation, tax year 2019
EIN 52-2396428 · Wellesley Hls, MA · Form 990, Schedule I · NTEE H83
In tax year 2019, Alzheimer's Disease Research Foundation (EIN 52-2396428) reported 67 grants paid totaling $15,431,965. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2019
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2019 | Massachusetts General Hospital Boston, MA | A | $1,475,000 | paid | ALZHEIMER'S GENOME PROJECT | 202041559349301614 |
| 2019 | The Broad Institute Inc Cambridge, MA | A | $750,000 | paid | PRODUCTION CENTER FOR REFERENCE AND VARIATION GENE-REGULARTORY MAPS | 202041559349301614 |
| 2019 | Amylyx Cambridge, MA | A | $750,000 | paid | PEGASUS CLINICAL STUDY OF AMX0035 IN ALZHEIMERS DISEASE; DRUG DEVELOPEMENT | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $350,000 | paid | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $345,000 | paid | ROLE IN MODULATING AB AND TAU-RELATED PATHOLOGIES AND NEURODENERATION | 202041559349301614 |
| 2019 | Brigham and Women's Hospital Boston, MA | A | $345,000 | paid | THE ROLE OF MFND-NEAURODEGENERATIVE CLEC7A+MICROGLIA IN AN AD MOUSE MODEL; TARGETING THE MICROBIOME AND MICROGLIA IN AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $345,000 | paid | INHIBITING CD33 FUNCTION AND MODULATING MICROGLIAL ACTIVATION STATE FOR ALZHEIMER'S DISEASE THERAPY | 202041559349301614 |
| 2019 | University of Southern California Los Angeles, CA | A | $345,000 | paid | MOLECULAR SIGNATURES OF APOE-MEDIATED BLOOD BRAIN BARRIER DYSFUNCTION CAUSING NEURONAL AND SYNAPTIC DYSFUNCATION | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $345,000 | paid | BERG BRAIN ENTRY & EXIT CONSORTIUM: CROSSTALK OF DNS BARRIERS AND CLEARANCE ROUTES IN HOMEOSTASIS AND AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $300,000 | paid | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | 202041559349301614 |
| 2019 | Boston Childrens Hospital Boston, MA | A | $298,115 | paid | MICROGLIAL HETEROGENEITY AND TRANSCIPTIONAL STATE CHANGES IN ALZHEIMER'S DISEASE. | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $287,500 | paid | ALZHEIMERS DISEASE-ASSOCIATED MUTATIONS IN PROTEIN KINASE C | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $287,500 | paid | HIGH THROUGH PUT DRUG SCREENING FOR AD USING 3D HUMAN NEURAL CULTURE SYSTEMS | 202041559349301614 |
| 2019 | Houston Methodist Hospital Foundation Houston, TX | A | $287,500 | paid | UNCOVERING THE MOLECULAR MECHANISM OF SELECTED DRUG CANDIDATES DERIVED FROM SYSTEMATIC ALZHEIMER'S DRUG REPOSITIONING | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | GUT MICROBIOME MEDIATED SHIFTS IN B-AMYLOID DEPOSITION IN A HUMANIZED AD MOUSE MODEL | 202041559349301614 |
| 2019 | Northwestern University Evanston, IL | A | $250,000 | paid | MOLECULAR AND CELLULAR MECHANISMS OF ACE1 R1279Q IN AD | 202041559349301614 |
| 2019 | New York University School of Medicine New York, NY | A | $250,000 | paid | NEUROTOXIC REACTIVE ASTROCYES IN ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $250,000 | paid | INTERPRETATION OF NON-CODING RISK ALLELES OF AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $250,000 | paid | NEUROIMMUNE MOLECULAR IMAGING: REDEFINING THE LANDSCAPE OF OPPORTUNITIES IN AD | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $250,000 | paid | ASSESSING THE LINKS BETWEEN THE MS4A RISK GENESE, MICROGLIA, AND ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | The University of California San Diego La Jolla, CA | A | $237,500 | paid | IDENTIYING THE BLOOD BRAIN BARRIER CHANGES DURING AD | 202041559349301614 |
| 2019 | The University of California San Diego La Jolla, CA | A | $230,000 | paid | THE EFFECT OF CHRONIC GAMMA-SECRETED MODULATION ON THE PREVENTION OF TBI-PROVOKED AND AD-RELEVANT BIOCHEMICAL PATHOLOGICAL AND BEHAVIORAL ALTERATIONS | 202041559349301614 |
| 2019 | University of Chicago Chicago, IL | A | $200,000 | paid | IN VITRO AND IN VIVO ANALYSIS OF AN APP VARIANT | 202041559349301614 |
| 2019 | Carnegie Mellon University Pittsburgh, PA | A | $199,013 | paid | CIRCUITS: INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANGER REGION | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $173,486 | paid | AD RISK IS HIGHER IN WOMEN: IDENTIFICATION OF FEMALE SPECIFIC BRAIN BIOENERGETIC TARGETS | 202041559349301614 |
| 2019 | University of Southern California Los Angeles, CA | A | $172,565 | paid | THE ROLE OF TREM2, APOE AND SEX | 202041559349301614 |
| 2019 | Palo Alto Veterans Institute for Research Palo Alto, CA | A | $172,500 | paid | REJUVENATION OF MICROGLIA IN BRAIN AGING AND NEURODEGENERATION | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | GENES TO THERAPIES CENTRALIZED RESEARCH CORE | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,500 | paid | MODELING AD IN SPECIFIC SUBTYPES OF HUMAN NEURONS THROUGH DIRECT NEURONAL REPROGRAMMING OF PATIENT FIBROBLASTS. | 202041559349301614 |
| 2019 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | EVALUATION OF THE EFFECT OF CELL TYPE- SPECIFIC DELETION OF ESCRT GENES ON THE SPREAD OF TAU PATHOLOGY | 202041559349301614 |
| 2019 | Sanford Burnham Prebys Medical Discovery Institute La Jolla, CA | A | $172,500 | paid | MECHANISMS FOR AD-ASSOCIATED DORLA MUTATIONS IN MICROGLIA AND NEURONS IN AD PATHOGENESIS | 202041559349301614 |
| 2019 | Mayo Clinic Jacksonville Jacksonville, FL | A | $172,500 | paid | 2019 FITZPATRICK PETRUCELLI: PT-BASE STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES. | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $172,500 | paid | ACTIVATION OF THE 26S PROTEASOME FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Whitehead Institute for Biomedical Research Cambridge, MA | A | $172,500 | paid | IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,500 | paid | IMAGING MICROGLIAL HOMEOSTASIS AND DISRUPTION P2RY12 RADIOTRACER DEVELOPMENT | 202041559349301614 |
| 2019 | University of Connecticut Health Center Farmington, CT | A | $172,500 | paid | PHYSIOLOGICAL METHOD FOR EARLY DETECTION OF SYNAPTIC VULNERABILITY IN AD MODEL ANIMALS | 202041559349301614 |
| 2019 | University of Texas Southwestern Medical Center Dallas, TX | A | $172,500 | paid | GENETIC TARGETS TO BLOCK TAU PROPAGATION: TEST KNOCKDOWN OF HSPG GENES IN VIVO | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $172,500 | paid | DIETARY SALT TAU PHOSPHRYLATION AND COGNITIVE IMPAIRMENT | 202041559349301614 |
| 2019 | Beth Israel Deaconess Medical Center Boston, MA | A | $172,500 | paid | UTILIZING FUNCTIONAL MAPS TO DISCOVER MICRO RNA'S IN AD | 202041559349301614 |
| 2019 | The Trustees of Boston University Boston, MA | A | $172,500 | paid | AD PHARMACOMICS IN 3D | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $172,500 | paid | HUMAN-SPECIFIC EVOLUTION OF CD33: EVOLUTIONARY RELATIONSHIP TO ANCIENT HOST-PATHOGEN INTERACTIONS AND CURRENT IMPLICATION FOR ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Mayo Clinic Rochester, MN | A | $172,500 | paid | THE ROLE OF CLUSTERIN IN TAU PATHOLOGY | 202041559349301614 |
| 2019 | The Rockefeller University New York, NY | A | $172,500 | paid | DISCOVERY OF CHEMICAL COMPOUNDS THAT INDUCE DEGRADATION OF APP-B-CTF IN CELLS | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,500 | paid | HARNESSING BIG DATA TO UNDERSTAND AD RISK | 202041559349301614 |
| 2019 | Yale University New Haven, CT | A | $172,500 | paid | ROLE OF MICROGLIAL PROTEIN SPARC IN CONTROL OF INFLAMMASOME ACTIVATION | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $172,497 | paid | THE CIRCADIAN CLOCK MODULATES NEURODENERATION IN AD VIA REVE-ERB | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $172,443 | paid | DIRECT MIGRATION OF MYELOID CELLS FROM THE SKULL MARROW TO THE BRAIN THROUGH ANATOMICAL CHANNELS ADDING FUEL TO THE FILE IN AD | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $171,914 | paid | INTERLEUKIN-3 IN AD | 202041559349301614 |
| 2019 | Harvard College Boston, MA | A | $171,523 | paid | ANALYTICAL AND STATISTICAL TOOLS FOR SEQUENCE ANALYSIS FOR ALZHEIMER'S DISEASE | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $154,701 | paid | CENTRAL CLOCK INFLUENCE ON ALZHEIMER'S DISEASE PATHOGENESIS | 202041559349301614 |
| 2019 | The Rockefeller University New York, NY | A | $150,000 | paid | STIMULATING PROTEASOME ACTIVITY FOR THE TREATMENT OF AD | 202041559349301614 |
| 2019 | Memorial Sloan Kettering Cancer Center New York, NY | A | $150,000 | paid | BIOCHEMICAL MAPPTING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULARS | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $150,000 | paid | STABLE ISOTOPE LABELING & QUANTITATIVE MASS SPECTOMETRY IMAGING OF AD PATHOLOGY IN HUMAN BRAIN | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $150,000 | paid | TARGETING REACTIVE ASTOCYTES FOR THERAPEUTIC INTERVENTION OF AD | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $150,000 | paid | BIOCHEMICAL MAPPING OF THE GSM BINDING SITE OF THE NOVEL PYRIDAZINE-DERIVED SMALL MOLECULE Y-SECRETASE MODULATORS | 202041559349301614 |
| 2019 | Icahn School of Medicine at Mount Sinai New York, NY | A | $150,000 | paid | VGF, A NOVEL THERAPEUTIC EFFECTOR OF AD PATHOGENESIS AND PROGRESSION | 202041559349301614 |
| 2019 | The Regents of the University of California Oakland, CA | A | $150,000 | paid | TREATING WITH GAMMA-SECRETASE MODULATORS TO PREVENT NEAURDENERATION IN MOUSE MODELS OF DOWN SYNDROME AND AD | 202041559349301614 |
| 2019 | Weill Medical College of Cornell University New York, NY | A | $150,000 | paid | REGULATION OF MIRCOGLIAL LYSOSOME ACIDIFICATION | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $115,000 | paid | HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATIC MODELS WITH APPLICATION TO AD | 202041559349301614 |
| 2019 | Northwestern University Evanston, IL | A | $115,000 | paid | THE ROLE OF IMPAIRED SYNAPTIC VESICLE MACHINERY PROTEOSTATSIS IN ALZHEIMER'S DISEASE PATHOGENESIS | 202041559349301614 |
| 2019 | The Salk Institute for Biological Studies La Jolla, CA | A | $115,000 | paid | IMPACT OF GENETIC, EPIGENETIC AND CELLULAR VARIANTS ON AD PATHOLOGY. | 202041559349301614 |
| 2019 | Massachusetts General Hospital Boston, MA | A | $108,726 | paid | AN INNOVATIVE STUDY OF THE PUPIL LIGHT REFLEX IN AD | 202041559349301614 |
| 2019 | Washington University St Louis St Louis, MO | A | $103,016 | paid | CHARACTERIZATION OF AD MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOICAL CONTINUUM | 202041559349301614 |
| 2019 | Massachusetts Institute of Technology Cambridge, MA | A | $100,000 | paid | HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO AD | 202041559349301614 |
| 2019 | Duke University School of Medicine Durham, NC | A | $91,687 | paid | A NOVEL APOE MIMETIC THERAPEUTIC PEPTIDE CN-105 ATTENUATES AD PATHOLOGY AND IMPROVES FUNCATIONAL OUTCOMES IN A MURINE MODEL OF AD | 202041559349301614 |
| 2019 | Columbia University New York, NY | A | $83,375 | paid | 2019 FITZPATRICK PETRUCELLI: PT BASED STRUCTURAL AND FUNCTIONAL BIOLOGY OF TAUOPATHIES | 202041559349301614 |
| 2019 | University of Rhode Island Kingston, RI | A | $56,404 | paid | CEREBROVASCULAR DYSFUNCTION IN AD: TARGETING THE MECHANISMS OF VASCULAR ACTIVATION | 202041559349301614 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.